scholarly journals May rotavirus vaccine be affect food allergy prevalence?

2020 ◽  
Vol 16 (8) ◽  
pp. 1952-1956
Author(s):  
Nazmi Mutlu Karakaş ◽  
Almina Arslan ◽  
Ece Atalay ◽  
Itır Ayli ◽  
Zeynep Ilayda Bağcı ◽  
...  
2020 ◽  
Vol 55 (1) ◽  
pp. 22-29 ◽  
Author(s):  
Mark Messina ◽  
Carina Venter

2020 ◽  
Vol 68 (6) ◽  
pp. 1152-1155
Author(s):  
Joan H Dunlop

The US Food and Drug Administration’s approval of a peanut oral immunotherapy product in January 2020 is a landmark development in the field of food allergy therapy. While food allergy prevalence has been increasing, this product is the first approved therapy for food allergy. Oral immunotherapy has many similarities to subcutaneous immunotherapy and drug desensitization protocols, but does not lead to sustained unresponsiveness. The studies leading to approval of the Palforzia product demonstrated increase in the amount of peanut protein able to be consumed, with 67% of subjects randomized to the treatment arm able to consume 600 mg of peanut protein in double-blind placebo-controlled food challenge at study exit. However, side effects are an important consideration, and dropout rates in studies of Palforzia ranged from 11% to 21%. Postmarketing surveillance of this product will be critical in assessing its long-term risks and benefits.


2020 ◽  
Vol 145 (2) ◽  
pp. AB182
Author(s):  
Andrea Pappalardo ◽  
Christopher Warren ◽  
Jialing Jiang ◽  
Ruchi Gupta

2014 ◽  
Vol 24 (7) ◽  
pp. 551-553 ◽  
Author(s):  
Jerel M. Ezell ◽  
Dennis R. Ownby ◽  
Edward M. Zoratti ◽  
Suzanne Havstad ◽  
Charlotte Nicholas ◽  
...  

Author(s):  
Jenny Garkaby ◽  
Larisa Epov ◽  
Nadira Musallam ◽  
Meital Almog ◽  
Ellen Bamberger ◽  
...  

2015 ◽  
Vol 3 (2) ◽  
pp. 291-293.e2 ◽  
Author(s):  
Lianne Soller ◽  
Moshe Ben-Shoshan ◽  
Daniel W. Harrington ◽  
Megan Knoll ◽  
Joseph Fragapane ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document